Treatment data before initiation of venetoclax treatment
| Variable . | N (%)∗ . |
|---|---|
| First-line treatment | |
| Intensive chemotherapy | 41 (51.3) |
| Less-intensive chemotherapy | 34 (42.5) |
| Nonchemotherapy | 5 (6.25) |
| Autologous HCT in first remission | |
| Yes | 26 (32.1) |
| No | 55 (67.9) |
| Rituximab maintenance | |
| Yes | 27 (35.5) |
| No | 49 (64.5) |
| Duration of first remission, median (range), y | 1.63 (0.04-6.4) |
| Relapse/progression within 24 mo of diagnosis | 39 (50.0) |
| Lines of treatment before venetoclax | |
| Median (range) | 3 (1-8) |
| ≥4 | 24 (29.6) |
| Treatments before venetoclax | |
| Anti-CD20 monoclonal antibody | 80 (98.8) |
| Alkylator | 75 (92.6) |
| BTKi | 74 (91.4) |
| Anthracycline | 47 (58.0) |
| Cytarabine | 45 (55.6) |
| Lenalidomide | 30 (37.0) |
| Bortezomib | 23 (28.4) |
| Platinum | 17 (21.0) |
| Phosphoinositide 3-kinase inhibitor | 7 (8.6) |
| Autologous HCT | 26 (32.1) |
| Allogeneic HCT | 3 (4.1) |
| CAR T-cell therapy | 2 (2.7) |
| Best response to BTKi | |
| CR | 14 (20.0) |
| PR | 32 (45.7) |
| SD | 4 (5.7) |
| PD | 20 (28.6) |
| ORR (CR + PR) | 46 (65.7) |
| Unknown | 4 |
| No previous BTKi | 7 |
| Reason for stopping BTKi | |
| PD | 59 (81.9) |
| Toxicity | 13 (18.2) |
| Duration of treatment with BTKi, median (range), mo | 6.4 (0.5-69) |
| Best response to last treatment before venetoclax | |
| CR, PR | 34 (45.3) |
| SD, PD | 41 (54.7) |
| Variable . | N (%)∗ . |
|---|---|
| First-line treatment | |
| Intensive chemotherapy | 41 (51.3) |
| Less-intensive chemotherapy | 34 (42.5) |
| Nonchemotherapy | 5 (6.25) |
| Autologous HCT in first remission | |
| Yes | 26 (32.1) |
| No | 55 (67.9) |
| Rituximab maintenance | |
| Yes | 27 (35.5) |
| No | 49 (64.5) |
| Duration of first remission, median (range), y | 1.63 (0.04-6.4) |
| Relapse/progression within 24 mo of diagnosis | 39 (50.0) |
| Lines of treatment before venetoclax | |
| Median (range) | 3 (1-8) |
| ≥4 | 24 (29.6) |
| Treatments before venetoclax | |
| Anti-CD20 monoclonal antibody | 80 (98.8) |
| Alkylator | 75 (92.6) |
| BTKi | 74 (91.4) |
| Anthracycline | 47 (58.0) |
| Cytarabine | 45 (55.6) |
| Lenalidomide | 30 (37.0) |
| Bortezomib | 23 (28.4) |
| Platinum | 17 (21.0) |
| Phosphoinositide 3-kinase inhibitor | 7 (8.6) |
| Autologous HCT | 26 (32.1) |
| Allogeneic HCT | 3 (4.1) |
| CAR T-cell therapy | 2 (2.7) |
| Best response to BTKi | |
| CR | 14 (20.0) |
| PR | 32 (45.7) |
| SD | 4 (5.7) |
| PD | 20 (28.6) |
| ORR (CR + PR) | 46 (65.7) |
| Unknown | 4 |
| No previous BTKi | 7 |
| Reason for stopping BTKi | |
| PD | 59 (81.9) |
| Toxicity | 13 (18.2) |
| Duration of treatment with BTKi, median (range), mo | 6.4 (0.5-69) |
| Best response to last treatment before venetoclax | |
| CR, PR | 34 (45.3) |
| SD, PD | 41 (54.7) |
Missing data: first-line treatment, n = 1; autologous HCT in first remission, n = 5; rituximab maintenance, n = 5; duration of first remission, n = 5; relapse/progression within 2 years of diagnosis, n = 3; best response to BTKi, n = 11; reason for stopping BTKi, n = 9; duration of treatment with BTKi, n = 10; and best response to last therapy before venetoclax, n = 6.